Archives of Gynecology and Obstetrics

, Volume 254, Issue 1–4, pp 685–690

Der Beitrag zur verbesserten Behandlung epithelialer Ovarialkarzinome: Aktuelle klinische Studien der kooperativen Arbeitsgruppe Ovarialkarzinom (GOCA)

  • H. G. Meerpohl
Gynäkologische Onkologie Gynäkologische Onkologie — Kooperative Studien — Stand Und Neugestaltung
  • 15 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Neijt, J.P., Ten Bokkel Huinink W.W:, Van der Burg, M.E.L., Van Oosterom, A.T. et al.: Randomized trial comparing two combination chemotherapy regimes (Hexa-CAF- vs CHAP-5) in advanced ovarian carcinoma The Lancet II 594–600Google Scholar
  2. 2.
    Neijt, J.P., Ten Bokkel, W.W., Van der Burg, M.E.L., Van Oosterom, A.T. et al Long term survival in ovarian cancer; matured data from the Netherlands Joint Study Group for ovarian cancer. Eur. J. Cancer Vol. 27, 1367–1372Google Scholar
  3. 3.
    Hamilton, T.C.: The biology of ovarian cancer Current Probl. Cancer 16, 1–57, 1992Google Scholar
  4. 4.
    Sessa, C., Zucchetti, M., Davoli, E., et al.: Phase I and clinical pharmacologic evaluation of aphidocolinglycynate J. Natl. Cancer Inst. 83, 1160–1169, 1991PubMedGoogle Scholar
  5. 5.
    Hamilton, T., O'Dwyer, P., Young, E. et al.: Phase I trial of buthionine sulfoxomine (BSO) plus melphalan (L-PAM) in patients with advanced cancer Proc. Am. Soc. Clin. Oncol. 9: 73, (abstr.)Google Scholar
  6. 6.
    McGuire, W.P., Hoskins, W.J., Brady, M.S. et al.: A phase III trial of dose intense versus standart dose cisplatin and cytoxan in advanced ovarian cancer Proc. Third Int. Gynecol. Cancer Soc. 35, (Abstr.)Google Scholar
  7. 7.
    Shea, T.C:, Flaherty, M., Elias, A. et al.: A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support J. Clin. Oncol. 651–661, 1989Google Scholar
  8. 8.
    Reed, E., Janik, J., Bookman, M. et al.: High dose carboplatin and rGM-CSF in refractory ovarian cancer Proc. ASCO 9: 609 (abstr.)Google Scholar
  9. 9.
    van der Hoop, R.G., Vecht, C.J., van der Burgh, M.E.L. et al: Prevention of cisplatin neurotoxicity with an ACTH (4–9) analogue in patients with ovarian cancer. N. Engl. J. Med. 322: 89–94, 1990PubMedGoogle Scholar
  10. 10.
    Manetta, A., MacNiell, C., Lyter, J.A. et al.: Hexamethylmelamine as a single second line agent in ovarian cancer Gynecol. Oncol. 36, 93–96, 1990CrossRefPubMedGoogle Scholar
  11. 11.
    Sutton, G.P., Blessing, J.A., Homesly, H.D. et al.: Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma J. Clin. Oncol. 7, 1672–1976, 1989PubMedGoogle Scholar
  12. 12.
    Thigpen, T., Blessing, J., Ball, H. et al.: Phase II trial of taxol as second line therapy for ovarian carcinoma: a Gynecologic Oncology Group Study Proc. ASCO 9, 156 (abstr.)Google Scholar
  13. 13.
    Howell, S.B., Kirmani, S., Lucas, E.W. et al: A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer j. Clin. Oncol. 8, 137–145, 1990PubMedGoogle Scholar
  14. 14.
    Karck, U., Zahradnik, H.P., Kiechle-Schwarz, M., Meerpohl, H.G. et al: Intraperitoneal therapy of patients with ovarian carcinoma and ascites with tumor necrosis factor Proc. Third. Int. Gynecol. Cancer Soc. 168, (abstr.)Google Scholar
  15. 15.
    Pujade-Lauraine, E., Colombo, N., Namer, N. et al: Intraperitoneal recombinant interferone at second look laparotomy Proc. ASCO 9, 156, (abstr.)Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • H. G. Meerpohl
    • 1
  1. 1.Universitäts-FrauenklinikFreiburg

Personalised recommendations